EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity

Shuchi Sehgal, Abhinav V Reddy, Suqi Ke, Colin S Hill iD, Timothy A Lin, Serena Mao, Lei Zheng, Jin He iD, Joseph M Herman, Chen Hu iD, Jeffrey J Meyer, Amol K Narang

Cancers · 29.04.2026 · 18 (9) · 1418

DOI: 10.3390/cancers18091418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 29.04.2026. Verfasst von Shuchi Sehgal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose/Objective: This purpose of this study is to report on a cohort of patients with Early-onset pancreatic cancer (EOPC) (age < 55 years) who were treated with neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) with or without surgical resection. Materials/Methods: This was a single-institution, retrospective review of patients with EOPC that was staged as either borderline resectable (BRPC) or locally advanced (LAPC) based on NCCN criteria and who were treated with upfront chemotherapy followed by SBRT, with or without subsequent surgical resection. Endpoints included overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and treatment-related toxicity.

Results

From 2016 to 2021, 47 patients met the inclusion criteria. The median age was 50.4 years (range, 36.4–54.7 years). The median duration of induction chemotherapy was 4 months (range, 2.5–9.0 months). The SBRT dose for the majority (46/47, 97.9%) of patients was 33 Gy in five fractions. Surgical resection was performed in 33 patients (70.2%). The median OS, LPFS, DMFS, and PFS were 14.2 months, 11.6 months, 8.9 months, and 8.1 months respectively. Six-month and 1-year LPFS were 88.3% and 45.4%, respectively. Chemotherapy duration (≥4 months) was associated with improved median OS (16.5 vs. 10.1 months, p = 0.005), LPFS (10.1 vs. 4.9 months, p = 0.002), DMFS (9.7 vs. 5.2 months, p = 0.014), and PFS (9.7 vs. 5.2 months, p = 0.020). The normalization of CA 19-9 (≤34 vs. >34 U/mL) after chemotherapy was associated with improved median DMFS (not reached vs. 5.6 months, p = 0.003) and PFS (11.3 vs. 5.6 months, p = 0.022). Grade 3+ rates of chemotherapy and radiation-related toxicity were 14.9% and 2.1% respectively. The Clavien–Dindo 3b toxicity rate was 3.0%.

Conclusions

In EOPC, an induction chemotherapy duration ≥4 months and the normalization of CA 19-9 after chemotherapy were associated with improved outcomes, suggesting a role for extended durations of systemic therapy titrated to CA 19-9 response before transitioning to local therapy. The high rate of local failure and the low rate of grade 3+ toxicity also suggest a role for intensifying local therapy in this population.

Schlagwörter

Stichwörter der Autor:innen

early onsetpancreatic adenocarcinomastereotactic body radiation therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Northside Radiation Oncology Consultants, Canton, GA 30115, USA.
  • Department of Radiation Oncology, NYU Langone Health, New York, NY 10016, USA.
  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • George Washington Medical Faculty Associates, Washington, DC 20037, USA.
  • Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

ORCID-Profile: Colin S Hill, Jin He, Chen Hu

Zitieren

APA

Sehgal, S., Reddy, A. V., Ke, S., Hill, C. S., Lin, T. A., Mao, S., Zheng, L., He, J., Herman, J. M., Hu, C., Meyer, J. J., & Narang, A. K. (2026). Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Cancers, 18(9), 1418. https://doi.org/10.3390/cancers18091418

Vancouver

Sehgal S, Reddy AV, Ke S, Hill CS, Lin TA, Mao S, et al. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Cancers. 2026;18(9):1418. doi:10.3390/cancers18091418

BibTeX
@article{Sehgal2026,
  author = {Sehgal, Shuchi and Reddy, Abhinav V and Ke, Suqi and Hill, Colin S and Lin, Timothy A and Mao, Serena and Zheng, Lei and He, Jin and Herman, Joseph M and Hu, Chen and Meyer, Jeffrey J and Narang, Amol K},
  title = {Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1418},
  doi = {10.3390/cancers18091418}
}
Kostenlos starten →